Eli Lilly and Company Revenue 2007–2025
Eli Lilly and Company reported $65.18B of revenue for fiscal 2025. That was 44.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +165.6%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $65.18B | +44.7% |
| FY 2024 | $45.04B | +32.0% |
| FY 2023 | $34.12B | +19.6% |
| FY 2022 | $28.54B | +0.8% |
| FY 2021 | $28.32B | +15.4% |
| FY 2020 | $24.54B | +9.9% |
| FY 2019 | $22.32B | +3.8% |
| FY 2018 | $21.49B | +7.6% |
| FY 2017 | $19.97B | -5.9% |
| FY 2016 | $21.22B | +6.3% |
| FY 2015 | $19.96B | +1.7% |
| FY 2014 | $19.62B | -15.1% |
| FY 2013 | $23.11B | +2.3% |
| FY 2012 | $22.60B | -6.9% |
| FY 2011 | $24.29B | +5.2% |
| FY 2010 | $23.08B | +5.7% |
| FY 2009 | $21.84B | +7.2% |
| FY 2008 | $20.37B | +9.3% |
| FY 2007 | $18.63B | — |
Source: Eli Lilly and Company SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open LLY 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Eli Lilly and Company reported $65.18B of revenue for fiscal 2025. That was 44.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +165.6%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Eli Lilly and Company
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeEli Lilly and Company — frequently asked questions
What is Eli Lilly and Company's revenue?
Eli Lilly and Company (LLY) reported revenue of $65.18B for fiscal year 2025, per its SEC filings.
How has Eli Lilly and Company's revenue changed over time?
Between fiscal 2007 and 2025, LLY's revenue grew at roughly 7.2% per year (compound annual rate), from $18.63B to $65.18B.
Where does this data come from?
Figures are computed from Eli Lilly and Company's official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.